ATG16L2 and lung cancer: Recently, Wen et al. (2018) found ATG16L2 rs10898880 contributed to a better prognosis of patients with non‐small cell lung cancer (NSCLC) after definitive radiotherapy, and a greater risk of developing severe radiation pneumonitis.